{"id":119045,"date":"2026-08-22T11:25:09","date_gmt":"2026-08-22T11:25:09","guid":{"rendered":"https:\/\/www.europesays.com\/ch\/119045\/"},"modified":"2026-08-22T11:25:09","modified_gmt":"2026-08-22T11:25:09","slug":"roche-stock-holds-firm-after-half-year-sales-reached-chf-30-4-billion","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ch\/119045\/","title":{"rendered":"Roche stock holds firm after half-year sales reached CHF 30.4 billion"},"content":{"rendered":"<p>Roche Holding AG (CH0012032048) is being priced against CHF 30.4 billion in first-half 2026 sales and a Swiss close of CHF 375.60 on August 21, 2026.<\/p>\n<p>The company&#8217;s half-year update on <a href=\"https:\/\/www.roche.com\/\" title=\"Roche half year results 2026\" rel=\"nofollow noopener\" target=\"_blank\">Roche&#8217;s investor page<\/a> says sales rose 6% at constant exchange rates in the first six months of 2026, while the same update puts dividend yield for FY 2025 at 3.2% and the next report at October 22, 2026.<\/p>\n<p>Sales and valuation<\/p>\n<p>That pairing matters for Roche shares because the current quote set also shows a market capitalization of $371.39 billion and a one-year gain of 40.78% on the same Swiss line, with the latest Deutsche Boerse quote at EUR 406.00 and +1.35% on August 21, 2026.<\/p>\n<p>On the trading screen, the Swiss line closed at CHF 375.60, the 52-week high stands at CHF 418, and the 52-week low is CHF 283.40. The stock has also gained 11.29% in 2026 and 5.24% over one week.<\/p>\n<p>What changed in the half-year<\/p>\n<p>The half-year sales figure of CHF 30.4 billion is the most important current operating number, and the 6% CER growth rate gives investors a simple comparison with the prior-year base. It also helps explain why Roche still trades with a large market value despite a six-month performance of -0.20% on the Swiss line.<\/p>\n<p>Volume context is equally notable: the Swiss line showed 7.65M CHF of volume on the quoted session, while the OTC line RHHBY traded at $58.10 and up 1.48% on August 21, 2026. The market is still giving Roche a premium valuation rather than a distressed one.<\/p>\n<p>More on Roche&#8217;s business<\/p>\n<p>Roche combines pharmaceuticals and diagnostics, and the company page highlights both as the core of its business model. The half-year result sits inside that mix, with the investor page emphasizing sales growth rather than a margin breakdown.<\/p>\n<p>Roche shares on the screen<\/p>\n<p>Roche shares ended the latest completed Swiss session at CHF 375.60, while the OTC Markets line for RHHBY stood at $58.10 and the market cap was $371.39 billion. That leaves the stock within a broad range but still well above the year low of CHF 283.40.<\/p>\n<p>Investor information<\/p>\n<p>Company: Roche Holding AG<\/p>\n<p>ISIN: CH0012032048<\/p>\n<p>Ticker: ROP<\/p>\n<p>Exchange: Swiss Exchange<\/p>\n<p>Price (as of August 21, 2026): CHF 375.60<\/p>\n<p>Market cap: $371.39 billion<\/p>\n<p>Sector \/ Industry: Pharmaceuticals \/ Pharmaceuticals and diagnostics<\/p>\n<p>Index membership: SMI<\/p>\n<p>Next earnings date: October 22, 2026<\/p>\n<p>&#13;<br \/>\n\t\t    Disclaimer&#8230;&#13;\n\t\t<\/p>\n","protected":false},"excerpt":{"rendered":"Roche Holding AG (CH0012032048) is being priced against CHF 30.4 billion in first-half 2026 sales and a Swiss&hellip;\n","protected":false},"author":2,"featured_media":119046,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[124],"tags":[14886,134,473],"class_list":["post-119045","post","type-post","status-publish","format-standard","has-post-thumbnail","category-roche","tag-ch0012032048","tag-roche","tag-roche-holding-ag"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ch\/117138917013065753","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/119045","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=119045"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/119045\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/119046"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=119045"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=119045"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=119045"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}